Koliber Biosciences

Executive Summary

Koliber Biosciences, founded in 2018 and headquartered in Cambridge, MA, is a data science company specializing in applying machine learning and artificial intelligence to accelerate biological discoveries. The company offers a comprehensive suite of services ranging from traditional statistical analyses to advanced predictive algorithms, targeting researchers and business leaders in the biotech and healthcare sectors. Currently in the Phase 1 stage, Koliber aims to transform complex data into actionable insights, enabling faster and more efficient drug development and research. While the company has not disclosed its total funding or valuation, its focus on AI-driven solutions positions it well in a rapidly growing market where data analytics is increasingly critical for success. The competitive landscape includes both established analytics providers and emerging AI startups, but Koliber's specific emphasis on biological discovery and its location in a biotech hub may provide distinct advantages. However, as a private, early-stage company without a disclosed pipeline or commercial products, its near-term revenue and impact remain uncertain.

Upcoming Catalysts (preview)

• Q3 2026Partnership Announcement with Major Pharmaceutical Company35% success
• Q4 2026Launch of Next-Generation AI-Powered Drug Discovery Platform40% success
• Q2 2026Series A Funding Round Closure55% success